Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Mankind Pharma, Alkem Laboratories, Glenmark are some of the companies to have launched, making the drug affordable to most ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

The biggest advantage of the drug going off patent is that the prices will plummet. The patented medicine, sold as Jardiance, ...

Mankind Pharma has launched a generic version of Empagliflozin in India under the brands Empaglyde, Empagreat, and Dynaduo. The launch breaks cost barriers, offering the medication at competitive ...

Mankind Pharma launches affordable empagliflozin in India for diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:30 Hrs [IST] Mankind Pharma has launched its affordable gen ...